Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Inventory (2024 - 2025)

Outlook Therapeutics (OTLK) has disclosed Inventory for 2 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 11.21% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2025, up 11.21% year-over-year, with the annual reading at $3.3 million for FY2025, N/A changed from the prior year.
  • Inventory for Q4 2025 was $3.5 million at Outlook Therapeutics, up from $3.3 million in the prior quarter.
  • The five-year high for Inventory was $4.1 million in Q2 2025, with the low at $3.1 million in Q4 2024.